Buy tech sell-off, Wedbush’s Ives says: ’this is a 1996 moment, not 1999’
LONDON - Scancell Holdings plc (AIM:SCLP), a developer of cancer immunotherapies, will hold its Annual General Meeting (AGM) on Thursday, October 30, 2025, at 3:00 p.m. GMT at the offices of Cooley (UK) LLP in London, the company announced Friday.
Following the AGM, Scancell’s senior management team will present the final results for the financial year ended April 30, 2025, and conduct a question-and-answer session. Shareholders are invited to attend the event in person.
The company stated that its Annual Report and Accounts for the year ended April 30, 2025, will be distributed to shareholders shortly and is currently available on the company’s website. The Notice of AGM has also been made available on the company’s website under the documents and presentations section.
Scancell is a clinical-stage biotechnology company that develops targeted immunotherapies designed to generate tumor-specific immunity. The company’s product portfolio includes iSCIB1+, which is currently in a Phase 2 trial for melanoma, and Modi-1, which is being investigated in a Phase 2 study across various solid tumors.
The company also operates a wholly owned subsidiary, GlyMab Therapeutics Ltd., which focuses on developing antibodies targeting tumor-specific glycans. Two of these antibodies have been licensed and are being developed by Genmab A/S.
This information is based on a press release statement issued by the company.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.